Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

Novo Nordisk (NVO) and Pfizer (PFE) are two major pharmaceutical companies that are both facing significant challenges and opportunities in the rapidly growing field of obesity treatments. Novo Nordisk has established itself as a leader in medications for weight loss and diabetes, with a strong presence in over 170 countries. The company's focus on treating chronic diseases has resulted in impressive financial performance, with revenue reaching $49.3 billion in the 12 months ending September 30, 2026, a growth rate of approximately 5.7%.

Net income for the same period was $16.7 billion, yielding a net margin of around 34%. However, Novo Nordisk faces intense competition in the weight-loss market, with other players like Eli Lilly entering the GLP-1 space. The company also deals with manufacturing constraints and potential pricing pressure from government and private payers.

Pfizer, on the other hand, is a diversified biopharmaceutical giant with a vast portfolio of vaccines and medicines. The company generated approximately $63.6 billion in revenue in the 12 months ending September 27, 2026, representing a growth rate of close to 1.3%. Net income for the same period was $4.0 billion, resulting in a net margin of about 6.3%.

Despite recent pricing pressures and reimbursement challenges, Pfizer is actively pursuing new drug development and acquisitions, such as its recent acquisition of oncology specialist Seagen. With a lower Forward P/E and P/S ratio compared to Novo Nordisk, Pfizer appears to be the more affordable option for investors looking for long-term growth potential.

However, Novo Nordisk's premium valuation reflects its strong growth prospects and competitive moat through its blockbuster drugs and patents on injectable Ozempic/Wegovy until 2032. As both companies navigate the complexities of the pharmaceutical industry, investors must weigh the risks and rewards of each stock to determine which aligns better with their long-term investment goals.